Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
$2.80
+2.6%
$2.72
$0.91
$9.40
$50.38MN/A6.77 million shs1.04 million shs
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$4.61
+0.2%
$3.35
$2.18
$7.90
$49.50M0.7523,618 shs19,793 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19171,481 shs4.12 million shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.70
+2.2%
$4.77
$0.53
$5.25
$47.32M-1.668,920 shs2,447 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
+2.56%-5.72%+3.32%-37.08%+279,999,900.00%
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
+1.10%+17.45%+32.47%+64.64%-29.40%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+0.62%-72.22%
OpGen, Inc. stock logo
OPGN
OpGen
+2.17%+3.30%-3.69%+12.71%+50.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/AN/AN/AN/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1.1334 of 5 stars
0.04.00.00.02.11.70.6
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
0.00
N/AN/AN/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/AN/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$70.67M0.70N/AN/A$7.39 per share0.62
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M17.70N/AN/A($11.55) per share-0.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/A0.00N/AN/AN/AN/AN/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$47.49M-$1.89N/AN/A-45.41%-38.33%-25.34%8/28/2025 (Estimated)
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%N/A

Latest ENZ, BMGL, BNR, and OPGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/6/2025Q1 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.17N/A-$0.17N/A$18.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/AN/AN/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/AN/AN/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A
3.02
2.76
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45

Institutional Ownership

CompanyInstitutional Ownership
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%

Insider Ownership

CompanyInsider Ownership
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
N/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Basel Medical Group Ltd stock logo
BMGL
Basel Medical Group
3618.45 millionN/AN/A
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1,39010.76 million7.50 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable

Recent News About These Companies

OpGen Forms Joint Venture with European Bank
OpGen Appoints New COO and Company Secretary
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock Split
OpGen Announced 1-for-10 Reverse Stock Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

Basel Medical Group stock logo

Basel Medical Group NASDAQ:BMGL

$2.80 +0.07 (+2.56%)
As of 07/17/2025 04:00 PM Eastern

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$4.61 +0.01 (+0.22%)
Closing price 07/17/2025 03:57 PM Eastern
Extended Trading
$4.54 -0.07 (-1.54%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.70 +0.10 (+2.17%)
As of 07/17/2025 03:37 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.